Neurodegenerative disease companies develop therapeutics, diagnostics and research technologies for conditions involving the progressive loss of neurons and nervous system function. Their work aims to improve disease detection, slow progression and address the underlying biology of neurodegeneration.
This category includes companies working on:
Browse 101 UK neurodegenerative disease companies below.
AAV gene therapies for rare neurological diseases of childhood
BlackfinBio is a biotechnology company developing AAV-based gene therapies for rare neurodegenerative diseases of the central nervous system, with an initial focus on children.…
Novel peptide-based therapeutics and biomarkers for neurodegeneration
Neuro-Bio is a preclinical-stage biotechnology company developing a first-in-class therapeutic approach to Alzheimer's disease and related neurodegenerative disorders. Its…
Rare and serious disease therapeutics with Cambridge R&D hub
Insmed is a US biopharmaceutical company with commercial-stage and late-pipeline products spanning respiratory, inflammatory and rare neurological diseases. Its Cambridge facility…
Multiplexed LC-MS proteomics for biomarker development and clinical trials
Inoviv is a bioanalytical contract research company providing multiplexed, quantitative LC-MS targeted proteomics services to pharmaceutical and biotech clients. Its platform…
Human iPSC-derived cells and services for drug discovery research
Axol Bioscience is a biotechnology company manufacturing and supplying human induced pluripotent stem cell-derived cells and outsourced laboratory services for drug discovery and…
Global biopharma with UK R&D hub in Hertfordshire
Roche Products is the UK pharmaceutical arm of F. Hoffmann-La Roche, headquartered at Welwyn Garden City in Hertfordshire. The site employs over 1,900 people and serves as a…
AAV gene therapies for rare and neurological diseases
Spur Therapeutics is a clinical-stage biotechnology company developing adeno-associated virus-based gene therapies for serious chronic diseases. Its lead programme is a Phase I/II…
Single-cell omics analysis platform for precision neuroscience research
CellClar is a UK-based Community Interest Company developing an AI-assisted software platform for single-cell omics data analysis in precision medicine. Its flagship product is…
AI drug discovery platform targeting neurological diseases
CoSyne Therapeutics is a drug discovery company applying AI and computational methods to identify and develop therapeutics for neurological diseases. The company describes its…
Ex vivo haematopoietic stem cell gene therapies for rare genetic diseases
Orchard Therapeutics is a gene therapy company developing ex vivo haematopoietic stem cell therapies for rare genetic diseases, primarily severe neurometabolic and immunological…
AAV gene therapies for neurodegenerative diseases including FTD and ALS
AviadoBio is a clinical-stage gene therapy company developing AAV-based treatments for neurodegenerative diseases. Its lead programme, AVB-101, is in a Phase 1/2 trial for…
Integrated academic drug discovery facility for anti-infectives and innovative targets
The Drug Discovery Unit is an academic drug discovery facility at the University of Dundee, integrating medicinal chemistry, high-throughput screening, structural biology, cell…